Company Focus
Regeneron Pharmaceuticals Inc
Latest Regeneron Pharmaceuticals Inc News
Pharmaceutical
CNX Therapeutics and Legacy Pharma have entered into a US commercial partnership for the launch of Ethyol (amifostine), with availability expected from July 2026. 26 June 2026
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options.
Latest News & Features of interest to Regeneron Pharmaceuticals Inc
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire privately-held US biotech Actio Biosciences with the aim of expanding its epilepsy portfolio. 10 August 2026
Biotechnology
French rare diseases company Innate Pharma (and Swedish Orphan Biovitrum (Sobi) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase III study in cutaneous T-cell lymphoma (CTCL). 10 August 2026
Pharmaceutical
Danish-based, Swedish-listed biotech Saniona (OMX: SANION) said today that its UK partner AstronauTx has exercised an option to take exclusive worldwide rights to compounds emerging from the pair's ion channel collaboration, handing Saniona equity worth $5 million and keeping alive a milestone package of up to $172 million. 10 August 2026
Biotechnology
Japanese pharmaceutical company Eisai has officially launched Leqembi (lecanemab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). 10 August 2026
Pharmaceutical
Switzerland-headquartered Oculis Holding and Spain’s privately-held Accure Therapeutic have entered into an asset purchase agreement whereby Oculis will acquire all of Accure’s worldwide development and commercial rights to privosegtor. 10 August 2026
Pharmaceutical
M&A news continued last week, with Curium announcing it is acquiring fellow US radiopharmaceutical company Lantheum for around $8 billion. A heavily financial results week included second quarter figures from US pharma giants Merck & Co and Pfizer. Also of note, the US Food and Drug Administration finally granted approval for Replimune’s Tudriqev for melanoma. 9 August 2026
Pharmaceutical
Chinese biopharma TransThera Sciences' Yochanra (tinengotinib) has been approved in China for adults with advanced, metastatic or unresectable cholangiocarcinoma harboring a fibroblast growth factor receptor2 (FGFR2) fusion or rearrangement who have previously received systemic therapy and FGFR inhibitor treatment. 7 August 2026
Biosimilars
India’s Biocon has announced the commercial launch of Yesafili (aflibercept-jbvf) in the USA. 7 August 2026
Pharmaceutical
USA-based eye care specialist Tarsus Pharmaceuticals yesterday announced that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. 7 August 2026
Biotechnology
Vedanta Biosciences, a Cambridge, Massachusetts-based late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal disease, has secured $60 million in funding and named two new board appointments ahead of pivotal Phase III data for its lead candidate. 7 August 2026
Latest In Brief for Regeneron Pharmaceuticals Inc
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze